Compositions and methods for diagnosis and prediction of solid organ graft rejection
AssigneeImmucor Gti Diagnostics, Inc.
InventorMinnie M. Sarwal
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, compositions, systems, and kits for diagnosing acute rejection of solid organ transplants using at least 5 genes selected from a 10-gene panel.
Claims24
A method for aiding in the diagnosis of an acute rejection response in a subject who has received a solid organ allograft, the method comprising:
- a) detecting a gene expression level for at least five genes in a sample from the subject, wherein the at least five genes are selected from the group consisting of CFLAR, DUSP1, IFNGR1, ITGAX, MAPK9, NAMPT, NKTR, PSEN1, RNF130, and RYBP;
- and
- b) comparing the gene expression level to a reference expression level of the at least five genes, wherein a statistical difference or a statistical similarity between the gene expression level and the reference expression level of the at least five genes, thereby aiding in the diagnosis of an acute rejection response.
4-6. (canceled)
(canceled)
10-12. (canceled)
24-114. (canceled)
A method of treatment of an acute rejection in a subject who has received a solid organ allograft, comprising
- a) ordering a test comprising:
- i) detecting a gene expression level of at least five genes in a sample from the subject, wherein the at least five genes comprise CFLAR, DUSP1, IFNGR1, ITGAX, MAPK9, NAMPT, NKTR, PSEN1, RNF130, and RYBP;
- ii) comparing the gene expression level to a reference expression level of the at least five genes;
- iii) determining the subject has an acute rejection response based upon a statistical difference or a statistical similarity between the gene expression level and the reference expression level of the at least five genes;
- and
- b) increasing the administration of a therapeutically effective amount of one or more of a therapeutic agent in a subject with an acute rejection response, maintaining the administration of a therapeutically effective amount of one or more of a therapeutic agent in a subject without an acute rejection response, or decreasing the administration of a therapeutically effective amount of one or more of a therapeutic agent in a subject without an acute rejection response.
116-197. (canceled)
A kit for assessing an acute rejection response in a subject who has received a solid organ allograft, the kit comprising:
- a) a gene expression evaluation element for evaluating the level of at least five genes in a sample from the subject to obtain gene expression data, wherein the at least five genes are selected from the group consisting of CFLAR, DUSP1, IFNGR1, IFNGR1, ITGAX, MAPK9, NAMPT, NKTR, PSEN1, RNF130, and RYBP;
- b) a phenotype determination element, wherein the phenotype determination element is one or more of (i) a gene expression profile indicative of an acute rejection response or (ii) a gene expression profile expression profile indicative of an absence of an acute rejection response;
- c) a comparison element for comparing the gene expression data to the gene expression profile of (i) and/or (ii), wherein the comparison element compares the expression of the at least five;
- and
- d) a set of instructions for assessing acute rejection response in a subject who has received a solid organ allograft.
199-223. (canceled)
Dependencies are inferred from the claim text.